方法对比
并排查看您选择的方法;存在差异的行会高亮显示。
| 慢性呼吸疾病问卷× | MRC呼吸困难量表× | |
|---|---|---|
| 领域 | 呼吸病学 | 呼吸病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1987 | 1959 |
| 提出者≠ | Gordon H. Guyatt, McMaster University | Medical Research Council (UK) |
| 类型≠ | Self-report or interviewer-administered questionnaire | Clinician or self-rated ordinal scale |
| 开创性文献≠ | Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987). A measure of quality of life for clinical trials in chronic lung disease. Thorax, 42(10), 773-778. DOI ↗ | Van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607. DOI ↗ |
| 别名≠ | CRQ, Chronic Respiratory Q | MRC, MRC Dyspnea, Modified Borg |
| 相关 | 5 | 5 |
| 摘要≠ | The CRQ is a 20-item, four-domain questionnaire developed by Guyatt and colleagues at McMaster University in 1987 to measure health-related quality of life specifically in patients with chronic respiratory disease, particularly chronic obstructive pulmonary disease and cystic fibrosis. Uniquely, the CRQ can be administered by interview or self-report, and its four domains (dyspnea, fatigue, emotional function, mastery) directly address the multidimensional burden of chronic respiratory disease. The CRQ has demonstrated exceptional responsiveness to pulmonary rehabilitation and other interventions, making it a preferred outcome measure in respiratory research and clinical practice. | The MRC Dyspnoea Scale is a simple 5-grade ordinal classification of dyspnea severity based on the exertional threshold at which breathlessness limits activity. Developed by the UK Medical Research Council (MRC) in 1959, it remains one of the most widely used dyspnea assessments globally due to its brevity, ease of administration, and strong prognostic correlation in chronic obstructive pulmonary disease and other chronic respiratory diseases. The scale is used in clinical practice, epidemiological surveys, and longitudinal disease monitoring to grade symptom severity and guide treatment intensity. |
| ScholarGate数据集 ↗ |
|
|